The initial success and recent setbacks of Sanofi’s dengue vaccine

The Sanofi’s dengue vaccine has a new setback, after a re-analysis of the clinical trial data, the company found that the vaccine “in the longer term, more cases of severe disease could occur following vaccination,” according to the press release. We may have to see the full data of these analyses to comment further.

Despite this, a colleague showed me the stock of Sanofi in the New York Stock Exchange dropped:

You can see the stock price went down before the press release… Isn’t it cool to see human minds predict outcomes? 🙂 Just kidding…